Brendan Leighton
Research Subjects
Research Interests
Brendan Leighton has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ann-Cathrine Jönsson-Rylander
Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
2 shared publications - Margareta Behrendt
Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
2 shared publications - Suvi E. Heinonen
Medical Affairs, GSK, Helsinki, Finland
2 shared publications Andrea Ahnmark
CVMD iMED, AstraZeneca R&D, Gothenburg, Sweden
1 shared publication- Anita M. van Den Hoek
Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, The Netherlands
1 shared publication Anne-Christine Andréasson
CVMD iMED, AstraZeneca R&D, Gothenburg, Sweden
1 shared publication
Latest Publications
- Open Access
- 21 February 2019
- Published by Wiley in Journal of Diabetes Research
- Vol. 2019, 1-13
The APOE3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic AtherosclerosisBackground. There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/− (GK+/−) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice respond similarly to lipid-lowering and antidiabetic drugs as humans. The objective of this study was to evaluate/characterize the APOE3-Leiden.glucokinase+/− (E3L.GK+/−) mouse as a novel disease model to study the metabolic syndrome and diabetic complications. Methods. Female E3L.GK+/−, E3L, and GK+/− mice were fed fat- and cholesterol-containing diets for 37 weeks, and plasma parameters were measured throughout. Development of diabetic macro- and microvascular complications was evaluated. Results. Cholesterol and triglyceride levels were significantly elevated in E3L and E3L.GK+/− mice compared to GK+/− mice, whereas fasting glucose was significantly increased in E3L.GK+/− and GK+/− mice compared to E3L. Atherosclerotic lesion size was increased 2.2-fold in E3L.GK+/− mice as compared to E3L (), which was predicted by glucose exposure (, ). E3L and E3L.GK+/− mice developed NASH with severe inflammation and fibrosis which, however, was not altered by introduction of the defective GK phenotype, whereas mild kidney pathology with tubular vacuolization was present in all three phenotypes. Conclusions. We conclude that the E3L.GK+/− mouse is a promising novel diet-inducible disease model for investigation of the etiology and evaluation of drug treatment on diabetic atherosclerosis.- 21 February 2019
- Published by Wiley in Journal of Diabetes Research
- Vol. 2019, 1-13
Open AccessThe APOE3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic AtherosclerosisBackground. There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/− (GK+/−) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice respond similarly to lipid-lowering and antidiabetic drugs as humans. The objective of this study was to evaluate/characterize the APOE3-Leiden.glucokinase+/− (E3L.GK+/−) mouse as a novel disease model to study the metabolic syndrome and diabetic complications. Methods. Female E3L.GK+/−, E3L, and GK+/− mice were fed fat- and cholesterol-containing diets for 37 weeks, and plasma parameters were measured throughout. Development of diabetic macro- and microvascular complications was evaluated. Results. Cholesterol and triglyceride levels were significantly elevated in E3L and E3L.GK+/− mice compared to GK+/− mice, whereas fasting glucose was significantly increased in E3L.GK+/− and GK+/− mice compared to E3L. Atherosclerotic lesion size was increased 2.2-fold in E3L.GK+/− mice as compared to E3L (), which was predicted by glucose exposure (, ). E3L and E3L.GK+/− mice developed NASH with severe inflammation and fibrosis which, however, was not altered by introduction of the defective GK phenotype, whereas mild kidney pathology with tubular vacuolization was present in all three phenotypes. Conclusions. We conclude that the E3L.GK+/− mouse is a promising novel diet-inducible disease model for investigation of the etiology and evaluation of drug treatment on diabetic atherosclerosis. - Open Access
- 16 July 2017
- Published by Wiley in The Journal of Physiology
- Vol. 595 (17) , 5765-5780
Muscle carnitine availability plays a central role in regulating fuel metabolism in the rodent
Key points: Meldonium inhibits endogenous carnitine synthesis and tissue uptake, and accelerates urinary carnitine excretion, although the impact of meldonium‐mediated muscle carnitine depletion on whole‐body fuel selection, and muscle fuel metabolism and its molecular regulation is under‐investigated. Ten days of oral meldonium administration did not impact on food or fluid intake, physical activity levels or body weight gain in the rat, whereas it depleted muscle carnitine content (all moieties), increased whole‐body carbohydrate oxidation and muscle and liver glycogen utilization, and reduced whole‐body fat oxidation. Meldonium reduced carnitine transporter protein expression across muscles of different contractile and metabolic phenotypes. A TaqMan PCR low‐density array card approach revealed the abundance of 189 mRNAs regulating fuel selection was altered in soleus muscle by meldonium, highlighting the modulation of discrete cellular functions and metabolic pathways. These novel findings strongly support the premise that muscle carnitine availability is a primary regulator of fuel selectionin vivo. The body carnitine pool is primarily confined to skeletal muscle, where it regulates carbohydrate (CHO) and fat usage. Meldonium (3‐(2,2,2‐trimethylhydrazinium)‐propionate) inhibits carnitine synthesis and tissue uptake, although the impact of carnitine depletion on whole‐body fuel selection, muscle fuel metabolism and its molecular regulation is under‐investigated. Male lean Zucker rats received water (control,n = 8) or meldonium‐supplemented water (meldonium,n = 8) for 10 days [1.6 g kg−1body mass (BM) day−1days 1–2, 0.8 g kg−1 BM day−1thereafter]. From days 7–10, animals were housed in indirect calorimetry chambers after which soleus muscle and liver were harvested. Food and fluid intake, weight gain and physical activity levels were similar between groups from days 7 to 10. Compared to control, meldonium depleted muscle total carnitine (P < 0.001) and all carnitine esters. Furthermore, whole‐body fat oxidation was less (P < 0.001) and CHO oxidation was greater (P < 0.05) compared to the control, whereas soleus and liver glycogen contents were less (P < 0.01 andP < 0.01, respectively). In a second study, male Wistar rats received water (n = 8) or meldonium‐supplemented water (n = 8) as above, and kidney, heart and extensor digitorum longus muscle (EDL) and soleus muscles were collected. Compared to control, meldonium depleted total carnitine content (allP < 0.001), reduced carnitine transporter protein and glycogen content, and increased pyruvate dehydrogenase kinase 4 mRNA abundance in the heart, EDL and soleus. In total, 189 mRNAs regulating fuel selection were differentially expressed in soleus in meldoniumvs. control, and a number of cellular functions and pathways strongly associated with carnitine depletion were identified. Collectively, these data firmly support the premise that muscle carnitine availability is a primary regulator of fuel selectionin vivo.
- 16 July 2017
- Published by Wiley in The Journal of Physiology
- Vol. 595 (17) , 5765-5780
Open AccessMuscle carnitine availability plays a central role in regulating fuel metabolism in the rodent
Key points: Meldonium inhibits endogenous carnitine synthesis and tissue uptake, and accelerates urinary carnitine excretion, although the impact of meldonium‐mediated muscle carnitine depletion on whole‐body fuel selection, and muscle fuel metabolism and its molecular regulation is under‐investigated. Ten days of oral meldonium administration did not impact on food or fluid intake, physical activity levels or body weight gain in the rat, whereas it depleted muscle carnitine content (all moieties), increased whole‐body carbohydrate oxidation and muscle and liver glycogen utilization, and reduced whole‐body fat oxidation. Meldonium reduced carnitine transporter protein expression across muscles of different contractile and metabolic phenotypes. A TaqMan PCR low‐density array card approach revealed the abundance of 189 mRNAs regulating fuel selection was altered in soleus muscle by meldonium, highlighting the modulation of discrete cellular functions and metabolic pathways. These novel findings strongly support the premise that muscle carnitine availability is a primary regulator of fuel selectionin vivo. The body carnitine pool is primarily confined to skeletal muscle, where it regulates carbohydrate (CHO) and fat usage. Meldonium (3‐(2,2,2‐trimethylhydrazinium)‐propionate) inhibits carnitine synthesis and tissue uptake, although the impact of carnitine depletion on whole‐body fuel selection, muscle fuel metabolism and its molecular regulation is under‐investigated. Male lean Zucker rats received water (control,n = 8) or meldonium‐supplemented water (meldonium,n = 8) for 10 days [1.6 g kg−1body mass (BM) day−1days 1–2, 0.8 g kg−1 BM day−1thereafter]. From days 7–10, animals were housed in indirect calorimetry chambers after which soleus muscle and liver were harvested. Food and fluid intake, weight gain and physical activity levels were similar between groups from days 7 to 10. Compared to control, meldonium depleted muscle total carnitine (P < 0.001) and all carnitine esters. Furthermore, whole‐body fat oxidation was less (P < 0.001) and CHO oxidation was greater (P < 0.05) compared to the control, whereas soleus and liver glycogen contents were less (P < 0.01 andP < 0.01, respectively). In a second study, male Wistar rats received water (n = 8) or meldonium‐supplemented water (n = 8) as above, and kidney, heart and extensor digitorum longus muscle (EDL) and soleus muscles were collected. Compared to control, meldonium depleted total carnitine content (allP < 0.001), reduced carnitine transporter protein and glycogen content, and increased pyruvate dehydrogenase kinase 4 mRNA abundance in the heart, EDL and soleus. In total, 189 mRNAs regulating fuel selection were differentially expressed in soleus in meldoniumvs. control, and a number of cellular functions and pathways strongly associated with carnitine depletion were identified. Collectively, these data firmly support the premise that muscle carnitine availability is a primary regulator of fuel selectionin vivo.
- Open Access
- 28 September 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-11
Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice
Aim. Models combining diabetes and atherosclerosis are important in evaluating the cardiovascular (CV) effects and safety of antidiabetes drugs in the development of treatments targeting CV complications. Our aim was to evaluate if crossing the heterozygous glucokinase knockout mouse (GK+/−) and hyperlipidemic mouse deficient in apolipoprotein E (ApoE−/−) will generate a disease model exhibiting a diabetic and macrovascular phenotype.Methods. The effects of defective glucokinase on the glucose metabolism and on the progression and regression of atherosclerosis on high-fat diets were studied in both genders of GK+/−ApoE−/−and ApoE−/−mice. Coronary vascular function of the female GK+/−ApoE−/−and ApoE−/−mice was also investigated.Results. GK+/−ApoE−/−mice show a stable hyperglycemia which was increased on Western diet. In oral glucose tolerance test, GK+/−ApoE−/−mice showed significant glucose intolerance and impaired glucose-stimulated insulin secretion. Plasma lipids were comparable with ApoE−/−mice; nevertheless the GK+/−ApoE−/−mice showed slightly increased atherosclerosis development.Conclusions. The GK+/−ApoE−/−mice showed a stable and reproducible hyperglycemia, accelerated atherosclerotic lesion progression, and no lesion regression after lipid lowering. This novel model provides a promising tool for drug discovery, enabling the evaluation of compound effects against both diabetic and cardiovascular endpoints simultaneously in one animal model.
- 28 September 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-11
Open AccessHyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice
Aim. Models combining diabetes and atherosclerosis are important in evaluating the cardiovascular (CV) effects and safety of antidiabetes drugs in the development of treatments targeting CV complications. Our aim was to evaluate if crossing the heterozygous glucokinase knockout mouse (GK+/−) and hyperlipidemic mouse deficient in apolipoprotein E (ApoE−/−) will generate a disease model exhibiting a diabetic and macrovascular phenotype.Methods. The effects of defective glucokinase on the glucose metabolism and on the progression and regression of atherosclerosis on high-fat diets were studied in both genders of GK+/−ApoE−/−and ApoE−/−mice. Coronary vascular function of the female GK+/−ApoE−/−and ApoE−/−mice was also investigated.Results. GK+/−ApoE−/−mice show a stable hyperglycemia which was increased on Western diet. In oral glucose tolerance test, GK+/−ApoE−/−mice showed significant glucose intolerance and impaired glucose-stimulated insulin secretion. Plasma lipids were comparable with ApoE−/−mice; nevertheless the GK+/−ApoE−/−mice showed slightly increased atherosclerosis development.Conclusions. The GK+/−ApoE−/−mice showed a stable and reproducible hyperglycemia, accelerated atherosclerotic lesion progression, and no lesion regression after lipid lowering. This novel model provides a promising tool for drug discovery, enabling the evaluation of compound effects against both diabetic and cardiovascular endpoints simultaneously in one animal model.
- Open Access
- 1 July 1998
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 139 (1) , 118-122
Furosemide decreases the sensitivity of glucose transport to insulin in skeletal muscle in vitro
The effects of the diuretic furosemide on the sensitivity of glucose disposal to insulin were investigated in rat soleus muscle in vitro. At basal levels of insulin, the rates of 3-O-methylglucose transport, 2-deoxyglucose phosphorylation and lactate formation were not affected significantly by furosemide (0.5 mmol/l). However, furosemide significantly decreased these rates at physiological and maximal levels of insulin. The contents of 2-deoxyglucose and glucose 6-phosphate in the presence of furosemide were not significantly different from those in control muscles at all levels of insulin studied. It is concluded that furosemide decreases the sensitivity of glucose utilization to insulin in skeletal muscle by directly inhibiting the glucose transport process.
- 1 July 1998
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 139 (1) , 118-122
Open AccessFurosemide decreases the sensitivity of glucose transport to insulin in skeletal muscle in vitro
The effects of the diuretic furosemide on the sensitivity of glucose disposal to insulin were investigated in rat soleus muscle in vitro. At basal levels of insulin, the rates of 3-O-methylglucose transport, 2-deoxyglucose phosphorylation and lactate formation were not affected significantly by furosemide (0.5 mmol/l). However, furosemide significantly decreased these rates at physiological and maximal levels of insulin. The contents of 2-deoxyglucose and glucose 6-phosphate in the presence of furosemide were not significantly different from those in control muscles at all levels of insulin studied. It is concluded that furosemide decreases the sensitivity of glucose utilization to insulin in skeletal muscle by directly inhibiting the glucose transport process.
- 1 August 1997
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 25 (3) , 401S
Zaprmast raises glucose utilisation in SHR skeletal muscle
- 1 August 1997
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 25 (3) , 401S
Zaprmast raises glucose utilisation in SHR skeletal muscle